Round voting button logo

SR732

A resolution expressing the sense of the Senate that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science.

Introduced·5/14/26
Introduced
Introduced in Senate · May 18, 2026

May 14, 2026

Ms. Warren (for herself, Ms. Baldwin, Mr. Schumer, Mr. Wyden, Mrs. Murray, Ms. Smith, Ms. Alsobrooks, Mr. Bennet, Mr. Blumenthal, Ms. Blunt Rochester, Mr. Booker, Ms. Cantwell, Mr. Coons, Ms. Cortez Masto, Ms. Duckworth, Mr. Durbin, Mr. Fetterman, Mr. Gallego, Mrs. Gillibrand, Ms. Hassan, Mr. Heinrich, Mr. Hickenlooper, Ms. Hirono, Mr. Kaine, Mr. Kelly, Mr. Kim, Mr. King, Ms. Klobuchar, Mr. Luján, Mr. Markey, Mr. Merkley, Mr. Murphy, Mr. Ossoff, Mr. Padilla, Mr. Peters, Mr. Reed, Ms. Rosen, Mr. Sanders, Mr. Schatz, Mr. Schiff, Ms. Slotkin, Mrs. Shaheen, Mr. Van Hollen, Mr. Warner, Mr. Warnock, Mr. Welch, and Mr. Whitehouse) submitted the following resolution; which was referred to the Committee on Health, Education, Labor, and Pensions

RESOLUTION

Expressing the sense of the Senate that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science.

  1. (1) FDA policies affecting access to medication abortion care in the United States must be based on transparent scientific review of the full body of gold-standard medical evidence, as well as considerations of potential burdens on patient access and the health care delivery system, as required by the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.);
  2. (2) Congress has granted the FDA the authority to regulate prescription drug medications and medical devices based on scientific determinations of their safety and efficacy grounded in the best available peer-reviewed evidence-based science, and without political interference;
  3. (3) the FDA has performed multiple scientific reviews of mifepristone over 25 years, each time finding mifepristone to be safe and effective for pregnancy termination, including when mifepristone is prescribed through telemedicine and dispensed to eligible patients by mail or at a pharmacy, based on high-quality clinical research and real-world-safety data; and
  4. (4) preserving and expanding access to medication abortion care, including preserving the ability to prescribe mifepristone through telemedicine and dispense to eligible patients by mail or at a pharmacy, is important to ensure equitable access to abortion for patients harmed by statutory, regulatory, financial, and circumstantial restrictions that worsen reproductive health disparities for—
    1. (A) Black and Indigenous people;
    2. (B) people of color;
    3. (C) immigrants;
    4. (D) people with lower incomes;
    5. (E) people in rural communities;
    6. (F) LGBTQ+ people;
    7. (G) people living with disabilities;
    8. (H) people experiencing intimate partner violence; and
    9. (I) people in other marginalized communities.